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INTRODUCTION
Hypoxia is an important factor in the progression
of solid tumors and has been associated with vari-
ous indicators of tumor angiogenesis as well as me-
tastasis. The presence of widespread hypoxia in tu-
mors has been associated with reduced survival
following radiotherapy, surgery and chemotherapy.
In radiotherapy, for example, hypoxic tumor cells
are significantly less responsive to radiotherapy
than their well-oxygenated counterparts because the
oxygen-derived free radicals needed to potentiate
ionizing radiation-induced DNA damage are reduced
or absent in hypoxic cells (1). In a number of hu-
man malignant tumors, hypoxia is associated with
poor outcome irrespective of the treatment modal-
ity used (2-5).
HIF-1 and HIF-2 are two closely related protein
complexes that activate transcription of target genes
in response to hypoxia. HIF-1 consists of a heterodi-
ORIGINAL
Prognostic significance of HIF-2 expression on tumor
infiltrating macrophages in patients with uterine cer-
vical cancer undergoing radiotherapy
Takashi Kawanaka1, Akiko Kubo1, Hitoshi Ikushima1, Toshiaki Sano2,
Yoshihiro Takegawa3, and Hiromu Nishitani1
1Department of Radiology, 2Department of Human Pathology, Institute of Health Biosciences, The
University of Tokushima Graduate School, and 3Department of Radiologic Technology, School of
Health Sciences, The University of Tokushima, Tokushima, Japan
Abstract : Hypoxia-inducible factor (HIF)-2α, a basic helix-loop-helix (bHLH)-PAS pro-
tein, is the principal regulator of the hypoxic transcriptional response. An immunohisto-
chemical study reported strong HIF-2α expression in the cytoplasm of tumor infiltrative
macrophages (TIMs). Thus we assessed the expression of HIF-2α in human cervical cancer
tissue before radiation therapy and its relationship to the clinical outcome. Seventy three
patients with histologically proven primary advanced squamous cell carcinoma of the uter-
ine cervix underwent radiotherapy in Tokushima University Hospital after biopsy speci-
mens were taken. Among 73 specimens stained for HIF-2α, 53 (72.6%) exhibited HIF-2α
immunoreactivity in the TIMs. In only 5 of 73 cases, HIF-2α immunoreactivity was ob-
served in the nuclei of tumor cells. The HIF-2α positive cell count ratio in TIMs was as-
sociated with disease-free survival (DFS) with the worst DFS (p=0.024) being in cases in
the group with a high positive cell count ratio. A high HIF-2α positive cell count ratio in
TIMs increased the risk of local recurrence (p=0.0142). These findings might suggest that
the ratio of the HIF-2α positive cell in TIMs may be a new predictive indicator for prog-
nosis before radiation therapy for uterine cervical cancer. J. Med. Invest. 55 : 78-86, Feb-
ruary, 2008
Keywords : hypoxia, HIF-2 alpha, macrophage, uterine cervical cancer
Received for publication October 24, 2007 ; accepted December
11, 2007.
Address correspondence and reprint requests to TakashiKawanaka,
M.D., Department of Radiology, Institute of Health Biosciences,
The University of Tokushima Graduate School, Kuramoto-cho,
Tokushima 770-8503, Japan and Fax : +81-88-633-7174.
The Journal of Medical Investigation Vol. 55 2008
78
mer of HIF-1 α and HIF-1β, identical to the previ-
ously identified aryl hydrocarbon nuclear translo-
cator (ARNT). Both are members of a family of tran-
scription factors, termed bHLH/PAS proteins, which
control a variety of critical embryogenic and physi-
ological events. An alternative dimerization partner
for ARNT, which also transactivates genes via HIF
DNA recognition sites, has been identified and
termed endothelial PAS domain protein 1 (EPAS-1),
HIF-1α-like factor (HLF), and mouse HIF-related
factor (HRF). In keeping with its functional homol-
ogy with HIF-1α, this protein has been termed
HIF-2α. HIF-2 consists of a heterodimer of HIF-2α
and HIF-1β. Hypoxia, or genetic alterations of the
hypoxia signalling cascade (6, 7) leading to the con-
stitutive expression of HIF, could promote intense
and chaotic neovascularization that facilitates tu-
mour spread. It has now been firmly established
that HIF has important roles in tumour progression.
Several immunohistochemical analyses have indi-
cated that HIF-1α and HIF-2α are overexpressed
in primary and metastatic human cancers, and that
the level of expression, either as a result of tumour
hypoxia or genetic alterations, is correlated with tu-
mour angiogenesis and patient mortality (7, 8).
HIF-1α and HIF-2α protein expression was mainly
observed in nuclei of tumor cells in various human
cancer cells. Talks, et al . reported strong HIF-2α ex-
pression in the cytoplasm of tumor infiltrative macro-
phages (TIMs) (9). To our knowledge, there is no
published report of HIF-2α expression in TIMs in
human uterine cervical cancer. Therefore, we as-
sessed the expression of HIF-2α in human cervical
cancer and the relationship between its expression
and clinical outcomes.
MATERIALS AND METHODS
Patients
A retrospective analysis was done on all records of
patients with histologically proven primary advanced
squamous cell carcinoma of the cervix in the De-
partment of Radiology, Tokushima University Hos-
pital. Between December 1992 and March 2002, 73
patients with primary advanced squamous cell carci-
noma of the cervix underwent radiotherapy. The
clinical stage distribution according to the Interna-
tional Federation of Gynecology and Obstetrics
(FIGO) criteria (10) was as follows : Stage IB = 3
(4.1%), Stage IIA = 3 (4.1%), Stage IIB = 16 (21.9%),
Stage IIIA = 1 (1.4%), Stage IIIB = 35 (50%), Stage
IVA = 7 (9.6%) and Stage IVB = 8 (11.0%). Patients
were staged by use of chest radiography, intravenous
pyelography (IVP), blood chemistry, cystoscopy,
and rectosigmoidoscopy. Table 1 summarizes pa-
tient characteristics. Follow up and survival infor-
mation was obtained from hospital records.
All patients had biopsy specimens taken pre-
treatment from the exposed tumor on the cervix of
the uterus. All samples were immediately formalin-
fixed and embedded in paraffin.
Table 1. Patients characteristics and treatment methods
Number of patients 73
Age range (median, years old) 42-93, (70)
Follow up period, range (median, month) 1-114, (30)
Histological classification Squamouscell carcinoma 72
Stage (FIGO 1994) Ib 3
IIa 3
IIb 16
IIIa 1
IIIb 35
IVa 7
IVb 8
Brachytherapy LDR 48
HDR 25
Concurrent chemotherapy BOAI 14
Weekly CDDP 5
None 54
Maintenance chemotherapy With 29
Without 44
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Radiotherapy Technique
For patients with primary advanced carcinoma
of the cervix, radiotherapy consisting of a combi-
nation of intracavitary brachytherapy and exter-
nal beam irradiation has been used in our depart-
ment. Before August 1997, low dose rate intracav-
ity brachytherapy (LDR) was delivered with a Cs-
137 source. From September 1997, high dose rate
intracavity brachytherapy (HDR) was delivered with
an Ir-192 source.
External radiation therapy was performed with
6 MV X-rays using the anterior and posterior parallel
opposing field technique. Five fractions weekly, with
1.8 or 2.0 Gy per fraction, were delivered to the mid-
plane of the pelvis. The area of external radiation
therapy included both the primary tumor and the
regional lymph nodes. The fraction size was 1.8-2 Gy
and total dose to the whole pelvis was 36-52 Gy (me-
dian 48 Gy) in the LDR group with midline shield-
ing at 15-40 Gy (median 38 Gy), whereas in the
HDR group the fraction size was 1.8-2 Gy and the
total 40-50 Gy (median 45 Gy), with midline shield-
ing at 20-45 Gy (median 43 Gy).
In the LDR group, we delivered the intracavitary
irradiation either before or after external radiation
therapy using a T.A.O manual afterloading applica-
tion (11) with a Cs-137 source. The patient received
44-55 Gy (median 48 Gy) to point A with the exter-
nal radiation therapy being designed to bring the
dose to a total of 50-70 Gy through use of a midline
shield. In the HDR group, intracavitary irradiation
was delivered after external irradiation using a Modi-
fied Manchester Applicator, an Ir-192 source with
a remotely controlled after-loading system (RALS)
without general anesthesia. Once per week, at 6 Gy
per fraction, a total of 12-30 Gy was delivered to
point A.
Adjuvant therapy
Fourteen patients with locally advanced cancer
received intra-arterial chemotherapy using the bal-
loon occluded arterial infusion (BOAI) method and
5 patients received weekly cisplatin (CDDP) infu-
sion as concurrent chemotherapy. A total of 29 pa-
tients underwent oral administration of fluorouracil
or tegafur-uracil as maintenance chemotherapy.
Maintenance chemotherapy was performed continu-
ously for two years following radiation therapy.
Immunohistochemical study
A mouse monoclonal antibody (Mab), anti-EPAS-
1/HIF-2α (EP190b ; Novus Biologicals, Littleton,
CO, USA), was generated and characterized as re-
ported previously (9, 12). Immunostaining was per-
formed according to the Labeled StreptAvidin-Biotin
(LSAB) method (Dako, Carpinteria, CA, USA), us-
ing a streptavidin-biotin-horseradish peroxidase
complex. Briefly, deparaffinized and rehydrated sec-
tions were treated with 0.3% hydrogen peroxide
in methanol for 30 min at room temperature to block
endogenous peroxidase activity. Antigen retrieval
was achieved by a 750 W microwave in 10 mM cit-
rate buffer (pH 6.0) for 15 min. After blocking with
10% goat serum in PBS, sections were incubated
with the first antibody, and the reaction was carried
out at 4overnight. All initial antibodies used for
this study were tested for optimal dilutions, and a
moderate dilution was determined for the best
differentiation of tumor samples. We used 1 : 400-
diluted EPAS-1 Mab (1.125 μg/ml). For immuno-
histochemical detection of macrophages, dilution
of the Mabs anti-human CD68 (KP1, Novus Biologi-
cals, Littleton, CO, USA) was done at 1 : 800. Reac-
tions were visualized using the 3,3’-diaminobenidine
substrate chromogen system (DAB) (K3468, Dako,
Carpinteria, CA, USA). All IHC slides were counter-
stained by Mayer’s hematoxylin.
Quantification of the Immunohistochemical study
A quantification method for the TIMs and HIF-2α
in TIMs was based on a previous study (13, 14).
To summarize, for focal macrophage quantification,
all slides were first observed at low power magnifi-
cation (10) to select three areas of the highest
concentration of CD68. The numbers of positively
stained cells in the three areas were counted at high
power magnification (200). The average number
of stained cells in the three ‘hotspot’ areas was con-
sidered as the CD68 count. The number of HIF-2α
positively stained cells in the same area of the three
hotspots was counted at high power magnification
(200). The average count was considered as the
HIF-2α count. The average of the HIF-2α count was
divided by the average of the CD68 count, and the
HIF-2α/CD68 ratio was obtained.
Assessment was performed in blinded fashion and
independently by two investigators (T. K., A. K.).
We used the average data from the two investiga-
tors. Conflicting scores were resolved by discussion
over the microscope.
Statistical analysis
A computer software Stat View-J 5.0 statistical
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package (Abacus Concepts, Berkeley, CA, USA)
was used for all statistical analysis and generation of
survival curves. χ2 tests examined the relationships
between categorical tumor variables. Spearman-
rank correlations were used to investigate relation-
ships between continuous patient and tumor vari-
ables. Survival curves were plotted using the method
of Kaplan and Meier, and the Log-rank test was
used to evaluate differences between life tables. P
values less than 0.05 were considered significant.
RESULTS
HIF-2expression
In only 5 of 73 samples, HIF-2α immunoreactivity
was observed in nuclei of tumor cells. All of these ex-
pressions were observed to be very weak at a high
power field. No tumor cell contained immunoreac-
tive cytoplasm (Fig. 1).
CD68 immunoreactivity was detected in mono-
nuclear cells that were distributed mainly in the in-
terstitial tissue and slightly in the tumor paren-
chyma. These mononuclear cells were identified as
TIMs (Fig. 1). HIF-2α immunoreactivity in colocali-
zation with CD68 immunoreactive cells was found
in 53 (72.6%) of the 73 samples. All the positive HIF-
2α immunoreactivity in interstitial cells considered
as TIMs was in the cytoplasm and was even stronger
than that in tumor cells. The number of HIF-2α
counts in 73 samples ranged from 0 to 79 with a
median value of 14 (mean=18.7, SD=16.8), which
was used as the cutoff point for categorical analy-
sis. A group of 39 fell into the high HIF-2α count
category (53%). The number of CD68 counts in 73
samples ranged from 0 to 169 with a median value
of 57 (mean=62.4, SD=35.1). The high CD68 count
group contained 38 samples (52%) using the cut-
off point of 57. A positive correlation was found
between increasing CD68 count (as a continuous
variable) and increasing HIF-2α count (Spear-
man Rho=0.54, p0.0001). The HIF-2α/CD68 ra-
tio ranged from 0% to 100% with a median value of
23.2% (mean=29.2%, SD=25.7).
HIF-2expression and clinical futures
In this study, the cumulative overall 5-year local
control rate according to stage was 100% in stage I,
89% in stage II, 78% in stage III, 43% in stage IVa
and 25% in stage IVb. The cause-specific 5-year sur-
vival rate was 100% in stage I, 79% in stage II, 58%
in stage III, 43% in stage IVa and 13% in stage IVb.
These data show similar results to previous reports
on radiotherapy outcomes of uterine cervical cancer
from other institutes (15-18). Table 2 shows the dis-
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Fig. 1. Immunohistochemical study of HIF-2α and CD68 at hu-
man invasive uterine cervical cancer (squamous cell carcinoma)
On (A) HIF-2α and (B) CD68 in low power field (10), the uter-
ine cervical squamous carcinoma show common positive cells
observed in mainly interstitial tissue. On (C) HIF-2α and (D)
CD68 in high power field (200), both immunoreactivity was de-
tected in common mononuclear cells that are distributed mainly
in interstitial tissue and slightly in tumor parenchyma. In this case,
a few tumor cells show HIF-2α immunoreactivity in nuclei.
Table 2. Distribution of HIF-2α, CD68 and HIF-2α/CD68 in
FIGO classification
FIGO classification
n I II III IVa IVb
HIF-2α counts
(median = 14/HPF)
HIF-2α14 34 3 8 17 4 2
HIF-2α14 39 0 11 19 3 6
CD68 counts
(median = 57/HPF)
CD6857 35 2 11 16 3 3
CD6857 38 1 8 20 4 5
HIF-2α / CD68 ratio
(median = 23.2%)
HIF-2α/CD6823.2 35 3 7 21 2 2
HIF-2α/CD6823.2 38 0 12 15 5 6
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tribution of HIF-2α count, CD68 count and HIF-2α/
CD68 ratio in the FIGO classification. There were
relatively balanced distributions of classified HIF-2α
count, CD68 count and HIF-2α/CD68 ratio in the
FIGO classification.
The HIF-2α count, CD68 count and HIF-2α/
CD68 ratio were compared with DFS and cause-
specific survival (CSS). The HIF-2α count and CD68
count failed to achieve significance for either DFS
or CSS (Fig. 2 and 3). Only the HIF-2α/CD68 ratio
was associated with DFS (p=0.024) with cases in
the high category group having the worst DFS (Fig.
4). However the HIF-2α/CD68 ratio was not asso-
ciated with CSS. The distribution of the HIF-2α/
CD68 ratio is shown in Table 3. There was no corre-
lation between the HIF-2α/CD68 ratio and age, con-
Fig. 2. Kaplan-Meier curves of DFS and CSS based on HIF-2α expression in TIMs
Fig. 3. Kaplan-Meier curves of DFS and CSS based on CD68 expression in TIMs
Fig. 4. Kaplan-Meier curves of DFS and CSS based on HIF-2α/CD68 ratio
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current or maintenance chemotherapy, brachyther-
apy method, pretreatment hemoglobin level or
CD68 count. HIF-2α immunoreactivity in the nu-
clei of tumor cells had no relationship with DFS or
CSS. (Data not shown)
In 19 of 73 patients tumors have recurred during
our observation period. The high HIF-2α/CD68 ra-
tio group had a significantly increased risk of local
recurrence (p=0.0142) (Table 4).
DISCUSSION
To our knowledge, this is the first report about
HIF-2α in squamous cell carcinoma of the uter-
ine cervix. Major findings in this survey were that
most of the HIF-2α immunoreactivity in squamous
cell carcinoma of the uterine cervix was detected
in TIMs and the percentage of HIF-2α immunore-
activity in TIMs significantly correlated with DFS.
It is well established that, when exposed to low-
ered levels of oxygen, tissues compensate in a va-
riety of ways, ranging from systemic adjustments
caused by increased erythropoietin production to
tissue-specific effects of increased VEGF expression
and the largely cellular effects of increased glyco-
lysis (19). All of these adaptations to hypoxia are
regulated wholly or in part by the HIF complex. The
oxygen-regulated components of this complex are
the HIF-α subunits. To date, three members of the
HIF-α family have been cloned : HIF-1α, HIF-2α,
and HIF-3α. Of the three HIF-α subunits, the most
extensively characterized subunit regarding func-
tion is HIF-1α. Its hypoxia-induced stabilization and
the following induction of a number of target genes
seems to be a general response in most, if not all,
cells. In addition, these proteins have at least some
unique functions as revealed by their different tar-
get genes (20-24). By contrast, HIF-3α is involved
in downregulation of the hypoxic response via an
alternatively spliced transcription factor, which may
function as an inhibitor of HIF-1α (25, 26).
HIF-1α and HIF-2α expression are a significant
prognostic factor of various cancers treated by ra-
diotherapy (12, 27-30). In uterine cervical cancer,
some papers (31-34) reported that overexpression
of HIF-1α in pretreatment uterine cervical cancer
cells served as a predictive marker for poor prog-
nosis after treatment by radiotherapy. However,
there has been no study examining the relation-
ship between the expression of HIF-2α and uter-
ine cervical cancer. In this study, weak HIF-2α im-
munoreactivity in tumor cells was observed in only
five biopsy sections and was not associated with
prognosis. This difference in immunoreactivity be-
tween HIF-1α and HIF-2α in cervical cancer cell
seems to indicate that there are individual variations
in the hypoxic response. Findings relating to the
role of TIMs in cervical cancers have been contro-
versial. It has been noted that there are higher
Table 3. Distribution of HIF-2α/CD68 ratio
HIF-2α/CD68 ratio (%)
Over all
(n=73)
23.2
(n= 35)
23.2
(n= 38) P value
Age (meanSD) 70.311.2 71.512.0 70.810.8 p=0.794
Concurrent chemotherapy With 19 11 8
p=0.317
without 54 24 30
Brachytherapy LDR 48 25 23
p=0.227
HDR 25 10 15
Maintenance chemotherapy With 29 15 14
p=0.590
without 44 20 24
Pretreatment hemoglobin level,
meanSD (/mm3) 11.4
1.9 11.12.1 11.61.8 p=1.094
CD68 count,
meanSD(/HPF) 61.5
35.6 58.239.7 64.631.6 p=0.437
Table 4. Treatment failure pattern
HIF-2α/CD68 ratio (%)
23.2
(n= 35)
23.2
(n= 38)
Local only 2 7
Distant (With local) 5 (1) 5 (1)
Overall 7 12
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macrophage counts in invasive carcinomas as op-
posed to cervical squamous intraepithelial lesions
(35). In turn, squamous intraepithelial lesions con-
tain more macrophages than the normal cervix (36).
Davidson, et al . (37) looked at 75 cases of carci-
noma, staining the tissue with CD68 and two endo-
thelial markers, and evaluated the cases by light mi-
croscopy. Based on previous reports of an associa-
tion between TIM density, increased angiogenesis,
and poorer outcome in breast carcinoma (38), these
authors sought to evaluate the same in cervical can-
cer. No correlation was found between TIM count
and tumor stage, grade, or survival, nor with mi-
crovessel count.
Leek, et al . reported that HIF-2α expression in
TIMs was not associated with DFS but was mar-
ginally associated with overall survival in cases in
the high expression group which had worse survival
in invasive breast cancer (39). To our knowledge,
this was the only report which mentioned a corre-
lation between HIF-2α expression in TIMs and clini-
cal outcome. However in this study, HIF-2α expres-
sion in TIMs was associated with DFS. Addition-
ally there was a significant tendency for an increased
risk of local recurrence in cases with a high HIF-2α
expression in the TIM group. This recurrence pat-
tern suggests that the role of HIF-2α expression in
TIMs is more important in regional tumor devel-
opment than in distant metastasis. It seems that
HIF-2α secreted by TIMs is a very important key
factor in tumor survival. Thus if we can control TIM
behavior, it must then contribute to remission of
the tumor.
In conclusion, we evaluated HIF-2α expression in
uterine cervical cancer. Most of the HIF-2α expres-
sion was observed in TIMs and a high HIF-2α ex-
pression ratio in TIMs was associated with DFS
and local recurrence. These results demonstrated
that macrophages recruited into tumor tissue play
a role in promoting tumor growth and that HIF-2α
expression in TIMs is an important prognostic fac-
tor, especially for predicting future local recurrence
after radiotherapy in patients with advanced uter-
ine cervical cancer.
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